PMID- 20539907
OWN - NLM
STAT- MEDLINE
DCOM- 20110214
LR  - 20131121
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 104
IP  - 1
DP  - 2010 Jul
TI  - Future perspective of induced pluripotent stem cells for diagnosis, drug 
      screening and treatment of human diseases.
PG  - 39-44
LID - 10.1160/TH10-05-0269 [doi]
AB  - Recent advances in stem cell biology have transformed the understanding of cell 
      physiology and developmental biology such that it can now play a more prominent 
      role in the clinical application of stem cell and regenerative medicine. Success 
      in the generation of human induced pluripotent stem cells (iPS) as well as 
      related emerging technology on the iPS platform provide great promise in the 
      development of regenerative medicine. Human iPS cells show almost identical 
      properties to human embryonic stem cells (ESC) in pluripotency, but avoid many of 
      their limitations of use. In addition, investigations into reprogramming of 
      somatic cells to pluripotent stem cells facilitate a deeper understanding of 
      human stem cell biology. The iPS cell technology has offered a unique platform 
      for studying the pathogenesis of human disease, pharmacological and toxicological 
      testing, and cell-based therapy. Nevertheless, significant challenges remain to 
      be overcome before the promise of human iPS cell technology can be realised.
FAU - Lian, Qizhou
AU  - Lian Q
AD  - Cardiology Division, Department of Medicine, Li Ka Shing Faculty of Medicine, The 
      University of Hong Kong, Queen Mary Hospital, Hong Kong, HKSAR, China.
FAU - Chow, Yenyen
AU  - Chow Y
FAU - Esteban, Miguel Angel
AU  - Esteban MA
FAU - Pei, Duanqing
AU  - Pei D
FAU - Tse, Hung-Fat
AU  - Tse HF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20100610
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
SB  - IM
MH  - Animals
MH  - Cardiovascular Diseases/*diagnosis/pathology/physiopathology/*therapy
MH  - *Cell- and Tissue-Based Therapy/trends
MH  - Drug Evaluation, Preclinical
MH  - Humans
MH  - Induced Pluripotent Stem Cells/*metabolism/pathology
MH  - Regenerative Medicine
EDAT- 2010/06/12 06:00
MHDA- 2011/02/15 06:00
CRDT- 2010/06/12 06:00
PHST- 2010/05/13 00:00 [received]
PHST- 2010/05/26 00:00 [accepted]
PHST- 2010/06/12 06:00 [entrez]
PHST- 2010/06/12 06:00 [pubmed]
PHST- 2011/02/15 06:00 [medline]
AID - 10-05-0269 [pii]
AID - 10.1160/TH10-05-0269 [doi]
PST - ppublish
SO  - Thromb Haemost. 2010 Jul;104(1):39-44. doi: 10.1160/TH10-05-0269. Epub 2010 Jun 
      10.